Clinical trial NCT05367115: Verification of the Epidemiology and Mortality of Rare Diseases in Taiwan With Real-world Evidence
Official title: National Cheng Kung University Hospital
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rare Diseases
Epidemiology
Morbidity
Morality
Comorbidities and Coexisting Conditions
Health Care Utilization
Lead sponsor: National Cheng-Kung University Hospital
Sponsor class: OTHER
First posted: 2022-05-10
Enrollment: 5000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The rare disease patients are validated in the Taiwan catastrophic illness certification.

Brief summary: This study aims to explore the longitudinal incidence and prevalence trends of selected muscular and bone-related rare diseases, i.e., Familial Amyloidotic Polyneuropathy (FAP), Primary hyperoxaluria, Wilson's disease, Cystic fibrosis, Osteogenesis imperfecta, Porphyria, and Primary Paget disease, and analyze healthcare utilization.

Detailed description: A rare disease (RD) means any disease that affects a small percentage of the population. According to the "Rare Disease and Orphan Drug Act" in 2000, RD is defined as the prevalence of lower than 10,000 people in Taiwan, or with special circumstances, and announced after review by the "Review Committee for Rare Diseases and Orphan Drugs". There are many different causes of RD, such as genetic and infection. Although researchers have made progress in learning how to diagnose, treat, and even prevent a variety of RD, but there is still much to do because most rare diseases have no treatments. Due to the low morbidity rate and fewer numbers of people who suffer from RD, patients have been impacted by a severe pathology and insufficiently recognized, diagnosed, and cured. However, prevalence, healthcare utilization, and economic impacts of rare diseases based on real-world evidence are still unknown in the world, especially in Taiwan. In 2020, there were 226 diseases officially proclaimed as RD and 17,592 patients in Taiwan, and approved 108 orphan drugs and 40 special nutrients for treating those patients to reduce their financial burden.

Eligibility criteria: Inclusion Criteria:

* The RD patients were defined as at least two ambulatory care records or one inpatient record in one year with Familial Amyloidotic Polyneuropathy (FAP), Osteogenesis imperfecta, and Acute Hepatic Porphyria between 2009 and 2017.

Exclusion Criteria:

* The RD patients were diagnosed with Familial Amyloidotic Polyneuropathy (FAP), Osteogenesis imperfecta, and Acute Hepatic Porphyria before 2009.

Primary outcomes:
measure: Number of incidences
timeFrame: 12 years
measure: Number of prevalence
timeFrame: 12 years
measure: Number of death
timeFrame: 12 years
measure: Number of Health Care Utilization
timeFrame: 12 years
Secondary outcomes:
Other outcomes:
Locations:
city: Tainan
country: Taiwan
facility: Department of Family Medicine, National Cheng Kung Univ Hosp
Study officials:
affiliation: National Cheng Kung University
name: Chih-Hsing Wu, MD
role: STUDY_DIRECTOR
References: